NextCure, Inc. (NXTC)
| Market Cap | 29.30M +17.7% |
| Revenue (ttm) | n/a |
| Net Income | -40.97M |
| EPS | -8.27 |
| Shares Out | 4.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,676 |
| Open | 6.00 |
| Previous Close | 6.23 |
| Day's Range | 5.96 - 6.57 |
| 52-Week Range | 1.55 - 15.74 |
| Beta | 1.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 10, 2026 |
About NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as w... [Read more]
Financial Performance
Financial StatementsNews
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
BALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), today provided a business update and reported financial results for the third quarter ended September 30, 2026.
NextCure Earnings release: Q3 2026
NextCure released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
NextCure Quarterly report: Q3 2026
NextCure has published its Q3 2026 quarterly earnings report on November 10, 2026.
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001 Private placement and the previously announced ...
NextCure reports Q2 EPS ($2.80), consensus ($1.92)
“Following quarter end, we announced our proposed merger with Avere Therapeutics, together with Avere’s concurrent private financing expected to generate approximately $320 million in gross proceeds, ...
NextCure Quarterly report: Q2 2026
NextCure has published its Q2 2026 quarterly earnings report on August 6, 2026.
NextCure Earnings release: Q2 2026
NextCure released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
NextCure Slides: Corporate presentation
NextCure has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
NextCure trading halted, volatility trading pause
10:36 EDT NextCure (NXTC) trading halted, volatility trading pause
Why Is Penny Stock NextCure (NXTC) Up Today?
NextCure stock saw a major rally on Tuesday after the company revealed a merger agreement.
NextCure, Avere Therapeutics enter definitive merger agreement
06:02 EDT NextCure (NXTC), Avere Therapeutics enter definitive merger agreement
NextCure, Avere Therapeutics enter definitive merger agreement
NextCure (NXTC) and Avere Therapeutics, a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, announced they have entered into a definitive merger agr...
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
Avere Therapeutics' lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as...
NextCure Slides: Corporate presentation
NextCure has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
NextCure Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and incentive plan amendments, with all proposals approved by stockholders. No questions or comments were received from participants. Final voting results will be filed in a Form 8-K.
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, to...
NextCure Transcript: KOL event
SIM0505, a CDH6-targeting ADC, showed a 55% response rate in heavily pretreated gynecologic cancers, with favorable safety and low ILD risk. Dose optimization is ongoing, and the drug demonstrated robust efficacy in both ovarian and uterine serous carcinoma, including patients previously treated with other ADCs.
NextCure Press release: KOL event
NextCure issued a press release on June 2, 2026, disclosing material business information to investors.
NextCure Slides: KOL event
NextCure has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
NextCure share weakness overdone, says Lucid Capital
Lucid Capital analyst Christopher Liu says NextCure’s (NXTC) SIM0505 data “were relatively encouraging,” despite the shares trading down 45%. The weakness is overdone, and Lucid would be buyers at the...
NextCure presents Phase 1 data for SIM0505 in gynecologic cancers
NextCure (NXTC) and Simcere Zaiming Pharmaceutical announced positive Phase 1 dose escalation data for SIM0505, an antibody-drug conjugate targeting CDH6, presented at the American Society for Clinica...
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability ...
NextCure initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of NextCure (NXTC) with a Buy rating and $25 price target NextCure is a clinical stage biotechnology company focused on developing antibodydrug conjugates for cancer p...
NextCure reports Q1 EPS ($1.87), consensus ($2.03)
“Our SIM0505 program reached critical milestones this quarter, headlined by the U.S. Food and Drug Administration (FDA) granting Fast Track designation for platinum-resistant ovarian cancer and the up...